Pacira Biosciences (NASDAQ:PCRX) had its target price boosted by Northland Securities from $50.00 to $54.00 in a research report report published on Tuesday morning, The Fly reports. Northland Securities currently has a market perform rating on the stock.
Several other research firms also recently weighed in on PCRX. ValuEngine upgraded shares of Pacira Biosciences from a sell rating to a hold rating in a research report on Tuesday, March 17th. Zacks Investment Research cut Pacira Biosciences from a buy rating to a hold rating and set a $38.00 target price for the company. in a report on Friday, March 27th. Wedbush reaffirmed a buy rating and issued a $85.00 price target on shares of Pacira Biosciences in a research note on Tuesday, May 12th. Guggenheim assumed coverage on Pacira Biosciences in a research note on Tuesday, May 26th. They issued a neutral rating for the company. Finally, TheStreet raised shares of Pacira Biosciences from a d+ rating to a c- rating in a research note on Monday, May 11th. Eight analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus target price of $54.53.
Shares of PCRX stock opened at $52.47 on Tuesday. The company has a current ratio of 5.37, a quick ratio of 4.63 and a debt-to-equity ratio of 0.94. Pacira Biosciences has a 12-month low of $27.46 and a 12-month high of $53.05. The business’s 50 day moving average is $44.57 and its two-hundred day moving average is $42.08. The company has a market capitalization of $1.86 billion, a P/E ratio of -2,622.19, a P/E/G ratio of 2.22 and a beta of 1.31.
Pacira Biosciences (NASDAQ:PCRX) last released its quarterly earnings results on Thursday, May 7th. The company reported $0.53 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.30 by $0.23. The firm had revenue of $105.68 million for the quarter, compared to analysts’ expectations of $101.64 million. Pacira Biosciences had a negative net margin of 0.02% and a positive return on equity of 13.89%. The firm’s revenue for the quarter was up 15.7% compared to the same quarter last year. During the same quarter last year, the company earned $0.22 EPS. On average, research analysts predict that Pacira Biosciences will post 0.95 earnings per share for the current fiscal year.
In related news, VP Lauren Bullaro Riker sold 2,000 shares of the stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $42.81, for a total value of $85,620.00. Following the completion of the transaction, the vice president now directly owns 12,464 shares in the company, valued at $533,583.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO David M. Stack sold 17,111 shares of the firm’s stock in a transaction on Monday, June 8th. The stock was sold at an average price of $48.12, for a total value of $823,381.32. Following the sale, the chief executive officer now directly owns 184,020 shares of the company’s stock, valued at approximately $8,855,042.40. The disclosure for this sale can be found here. Insiders have sold 43,083 shares of company stock worth $2,019,772 over the last ninety days. 6.20% of the stock is owned by insiders.
A number of institutional investors and hedge funds have recently modified their holdings of PCRX. Thrivent Financial for Lutherans lifted its position in Pacira Biosciences by 0.7% in the fourth quarter. Thrivent Financial for Lutherans now owns 33,228 shares of the company’s stock valued at $1,505,000 after buying an additional 226 shares during the last quarter. UBS Asset Management Americas Inc. raised its stake in shares of Pacira Biosciences by 0.5% in the 4th quarter. UBS Asset Management Americas Inc. now owns 47,874 shares of the company’s stock valued at $2,169,000 after acquiring an additional 241 shares during the period. Alliancebernstein L.P. lifted its holdings in shares of Pacira Biosciences by 0.4% in the 4th quarter. Alliancebernstein L.P. now owns 64,814 shares of the company’s stock worth $2,936,000 after acquiring an additional 250 shares during the last quarter. Nisa Investment Advisors LLC boosted its position in shares of Pacira Biosciences by 4.0% during the 1st quarter. Nisa Investment Advisors LLC now owns 7,790 shares of the company’s stock worth $261,000 after purchasing an additional 300 shares during the period. Finally, Mutual of America Capital Management LLC increased its holdings in Pacira Biosciences by 21.2% in the 1st quarter. Mutual of America Capital Management LLC now owns 1,844 shares of the company’s stock valued at $62,000 after purchasing an additional 323 shares during the last quarter.
Pacira Biosciences Company Profile
Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure.
Receive News & Ratings for Pacira Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.